Caecal pH is a biomarker of excessive colonic fermentation

World Journal of Gastroenterology

Volumn 20, Issue 17, 2014, Pages 5000-5007

  Farmer, Adam D ^a   Mohammed, Sahar D ^a   Dukes, George E ^b   Mark Scott, S ^a   Hobson, Anthony R ^c  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b GLAXOSMITHKLINE   (United States)

^c Functional Gut Clinic   (United Kingdom)

Author keywords

Bloating; Caecal pH; Caecoparesis; Colonic microbiota; Fermentation

Indexed keywords

ADULT; AGED; ARTICLE; CAECAL PH; CAPSULE ENDOSCOPY; CLINICAL ARTICLE; COLONIC FERMENTATION; CONTROLLED STUDY; FEMALE; FERMENTATION; HUMAN; ILEOCECAL VALVE; INTESTINE MOTILITY; IRRITABLE COLON; PH; BACTERIA; CASE CONTROL STUDY; CECUM; GASTROINTESTINAL MOTILITY; IRRITABLE BOWEL SYNDROME; MALE; METABOLISM; MICROBIOLOGY; MIDDLE AGED; PATHOPHYSIOLOGY; TIME; YOUNG ADULT;

ADULT; BACTERIA; CAPSULE ENDOSCOPY; CASE-CONTROL STUDIES; CECUM; FEMALE; FERMENTATION; GASTROINTESTINAL MOTILITY; HUMANS; HYDROGEN-ION CONCENTRATION; IRRITABLE BOWEL SYNDROME; MALE; MIDDLE AGED; TIME FACTORS; YOUNG ADULT;

EID: 84899853271     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v20.i17.5000     Document Type: Article

References (49)

1. Jiang X, Locke GR, Choung RS, Zinsmeister AR, Schleck CD, Talley NJ. Prevalence and risk factors for abdominal bloating and visible distention: a population-based study. Gut 2008; 57: 756-763 [PMID: 18477677 DOI: 10.1136/gut.2007.142810]
2. Agrawal A, Houghton LA, Lea R, Morris J, Reilly B, Whorwell PJ. Bloating and distention in irritable bowel syndrome: the role of visceral nsation. Gastroenterology 2008; 134: 1882-1889 [PMID: 18455167 DOI: 10.1053/j.gastro.2008.02.096]
3. Jiang X, Locke GR, Zinsmeister AR, Schleck CD, Talley NJ. Health care seeking for abdominal bloating and visible distention. Aliment Pharmacol Ther 2009; 30: 775-783 [PMID: 19563502 DOI: 10.1111/j.1365-2036.2009.04080.x]
4. Tuteja AK, Talley NJ, Joos SK, Tolman KG, Hickam DH. Abdominal bloating in employed adults: prevalence, risk factors, and association with other bowel disorders. Am J Gastroenterol 2008; 103: 1241-1248 [PMID: 18422817 DOI: 10.1111/j.1572-0241.2007.01755.x]
5. Maxton DG, Morris JA, Whorwell PJ. Ranking of symptoms by patients with the irritable bowel syndrome. BMJ 1989; 299: 1138 [PMID: 2513023]
6. Chang L, Lee OY, Naliboff B, Schmulson M, Mayer EA. Sensation of bloating and visible abdominal distension in patients with irritable bowel syndrome. Am J Gastroenterol 2001; 96: 3341-3347 [PMID: 11774947 DOI: 10.1111/ j.1572-0241.2001.05336.x]
7. Tack J, Talley NJ. Functional dyspepsia--symptoms, definitions and validity of the Rome III criteria. Nat Rev Gastroenterol Hepatol 2013; 10: 134-141 [PMID: 23399526 DOI: 10.1038/nrgastro.2013.14]
8. Agrawal A, Houghton LA, Reilly B, Morris J, Whorwell PJ. Bloating and distension in irritable bowel syndrome: the role of gastrointestinal transit. Am J Gastroenterol 2009; 104: 1998-2004 [PMID: 19491831 DOI: 10.1038/ajg.2009.251]
9. Park HJ, Jarrett M, Cain K, Heitkemper M. Psychological distress and GI symptoms are related to severity of bloating in women with irritable bowel syndrome. Res Nurs Health 2008; 31: 98-107 [PMID: 18181134 DOI: 10.1002/nur.20237]
10. Haderstorfer B, Psycholgin D, Whitehead WE, Schuster MM. Intestinal gas production from bacterial fermentation of undigested carbohydrate in irritable bowel syndrome. Am J Gastroenterol 1989; 84: 375-378 [PMID: 2929557]
11. Maratka Z. Abdominal bloating and distension in functional gastrointestinal disorders-epidemiology and possible mechanisms. Aliment Pharmacol Ther 2008; 27: 713-714; author reply 714 [PMID: 18194494 DOI: 10.1111/j.1365-2036.2008.03616.x]
12. Pimentel M, Chow EJ, Lin HC. Eradication of small intestinal bacterial overgrowth reduces symptoms of irritable bowel syndrome. Am J Gastroenterol 2000; 95: 3503-3506 [PMID: 11151884 DOI: 10.1111/j.1572-0241.2000.03368.x]
13. Issa B, Wafaei NA, Whorwell PJ. Abdominal bloating and distension: what is the role of the microbiota. Dig Dis Sci 2012; 57: 4-8 [PMID: 21800157 DOI: 10.1007/s10620-011-1834-4]
14. Young VB, Schmidt TM. Overview of the gastrointestinal microbiota. Adv Exp Med Biol 2008; 635: 29-40 [PMID: 18841701 DOI: 10.1007/978-0-387-09550-9_3]
15. Cummings JH, Macfarlane GT. The control and consequences of bacterial fermentation in the human colon. J Appl Bacteriol 1991; 70: 443-459 [PMID: 1938669]
16. Shen Q, Zhao L, Tuohy KM. High-level dietary fibre upregulates colonic fermentation and relative abundance of saccharolytic bacteria within the human faecal microbiota in vitro. Eur J Nutr 2012; 51: 693-705 [PMID: 21952691 DOI: 10.1007/s00394-011-0248-6]
17. Cummings JH, Pomare EW, Branch WJ, Naylor CP, Macfarlane GT. Short chain fatty acids in human large intestine, portal, hepatic and venous blood. Gut 1987; 28: 1221-1227 [PMID: 3678950 DOI: 10.1136/gut.28.10.1221]
18. Mortensen FV, Nielsen H, Mulvany MJ, Hessov I. Short chain fatty acids dilate isolated human colonic resistance arteries. Gut 1990; 31: 1391-1394 [PMID: 2265780 DOI: 10.1136/ gut.31.12.1391]
19. Lewis SJ, Heaton KW. Increasing butyrate concentration in the distal colon by accelerating intestinal transit. Gut 1997; 41: 245-251 [PMID: 9301506 DOI: 10.1136/gut.41.2.245]
20. Watson BW, Meldrum SJ, Riddle HC, Brown RL, Sladen GE. pH profile of gut as measured by radiotelemetry capsule. Br Med J 1972; 2: 104-106 [PMID: 5018285 DOI: 10.1136/ bmj.2.5805.104]
21. Evans DF, Pye G, Bramley R, Clark AG, Dyson TJ, Hardcastle JD. Measurement of gastrointestinal pH profiles in normal ambulant human subjects. Gut 1988; 29: 1035-1041 [PMID: 3410329 DOI: 10.1136/gut.29.8.1035]
22. Zarate N, Mohammed SD, O'Shaughnessy E, Newell M, Yazaki E, Williams NS, Lunniss PJ, Semler JR, Scott SM. Accurate localization of a fall in pH within the ileocecal region: validation using a dual-scintigraphic technique. Am J Physiol Gastrointest Liver Physiol 2010; 299: G1276-G1286 [PMID: 20847301 DOI: 10.1152/ajpgi.00127.2010]
23. Tillisch K, Labus JS, Naliboff BD, Bolus R, Shetzline M, Mayer EA, Chang L. Characterization of the alternating bowel habit subtype in patients with irritable bowel syndrome. Am J Gastroenterol 2005; 100: 896-904 [PMID: 15784038 DOI: 10.1111/j.1572-0241.2005.41211.x]
24. Drossman DA. Rome III: the functional gastrointestinal disorders. 3rd ed. McLean, Va.: Degnon Associates, 2006
25. Sarosiek I, Selover KH, Katz LA, Semler JR, Wilding GE, Lackner JM, Sitrin MD, Kuo B, Chey WD, Hasler WL, Koch KL, Parkman HP, Sarosiek J, McCallum RW. The assessment of regional gut transit times in healthy controls and patients with gastroparesis using wireless motility technology. Aliment Pharmacol Ther 2010; 31: 313-322 [PMID: 19814743 DOI: 10.1111/j.1365-2036.2009.04162.x]
26. D'Agostino RB, Stephens MA. Goodness-of-fit techniques. New York: M. Dekker, 1986
27. Macfarlane GT, Gibson GR, Cummings JH. Comparison of fermentation reactions in different regions of the human colon. J Appl Bacteriol 1992; 72: 57-64 [PMID: 1541601 DOI: 10.1111/j.1365-2672.1992.tb04882.x]
28. Mortensen PB, Andersen JR, Arffmann S, Krag E. Shortchain fatty acids and the irritable bowel syndrome: the effect of wheat bran. Scand J Gastroenterol 1987; 22: 185-192 [PMID: 3033815 DOI: 10.3109/00365528708991878]
29. Treem WR, Ahsan N, Kastoff G, Hyams JS. Fecal short-chain fatty acids in patients with diarrhea-predominant irritable bowel syndrome: in vitro studies of carbohydrate fermentation. J Pediatr Gastroenterol Nutr 1996; 23: 280-286 [PMID: 8890079 DOI: 10.1097/00005176-199610000-00013]
30. Tana C, Umesaki Y, Imaoka A, Handa T, Kanazawa M, Fukudo S. Altered profiles of intestinal microbiota and organic acids may be the origin of symptoms in irritable bowel syndrome. Neurogastroenterol Motil 2010; 22: 512-519, e114-115 [PMID: 19903265 DOI: 10.1111/j.1365-2982.2009.01427.x]
31. Jeffery IB, O'Toole PW, Öhman L, Claesson MJ, Deane J, Quigley EM, Simrén M. An irritable bowel syndrome subtype defined by species-specific alterations in faecal microbiota. Gut 2012; 61: 997-1006 [PMID: 22180058 DOI: 10.1136/ gutjnl-2011-301501]
32. Arumugam M, Raes J, Pelletier E, Le Paslier D, Yamada T, Mende DR, Fernandes GR, Tap J, Bruls T, Batto JM, Bertalan M, Borruel N, Casellas F, Fernandez L, Gautier L, Hansen T, Hattori M, Hayashi T, Kleerebezem M, Kurokawa K, Leclerc M, Levenez F, Manichanh C, Nielsen HB, Nielsen T, Pons N, Poulain J, Qin J, Sicheritz-Ponten T, Tims S, Torrents D, Ugarte E, Zoetendal EG, Wang J, Guarner F, Pedersen O, de Vos WM, Brunak S, Doré J, Antolín M, Artiguenave F, Blottiere HM, Almeida M, Brechot C, Cara C, Chervaux C, Cultrone A, Delorme C, Denariaz G, Dervyn R, Foerstner KU, Friss C, van de Guchte M, Guedon E, Haimet F, Huber W, van Hylckama-Vlieg J, Jamet A, Juste C, Kaci G, Knol J, Lakhdari O, Layec S, Le Roux K, Maguin E, Mérieux A, Melo Minardi R, M'rini C, Muller J, Oozeer R, Parkhill J, Renault P, Rescigno M, Sanchez N, Sunagawa S, Torrejon A, Turner K, Vandemeulebrouck G, Varela E, Winogradsky Y, Zeller G, Weissenbach J, Ehrlich SD, Bork P. Enterotypes of the human gut microbiome. Nature 2011; 473: 174-180 [PMID: 21508958 DOI: 10.1038/nature09944]
33. van Zanten GC, Knudsen A, Röytiö H, Forssten S, Lawther M, Blennow A, Lahtinen SJ, Jakobsen M, Svensson B, Jes-persen L. The effect of selected synbiotics on microbial composition and short-chain fatty acid production in a model system of the human colon. PLoS One 2012; 7: e47212 [PMID: 23082149 DOI: 10.1371/journal.pone.0047212]
34. Pimentel M, Lembo A, Chey WD, Zakko S, Ringel Y, Yu J, Mareya SM, Shaw AL, Bortey E, Forbes WP. Rifaximin therapy for patients with irritable bowel syndrome without constipation. N Engl J Med 2011; 364: 22-32 [PMID: 21208106 DOI: 10.1056/NEJMoa1004409]
35. Shepherd SJ, Lomer MC, Gibson PR. Short-chain carbohydrates and functional gastrointestinal disorders. Am J Gastroenterol 2013; 108: 707-717 [PMID: 23588241 DOI: 10.1038/ ajg.2013.96]
36. Staudacher HM, Whelan K, Irving PM, Lomer MC. Comparison of symptom response following advice for a diet low in fermentable carbohydrates (FODMAPs) versus standard dietary advice in patients with irritable bowel syndrome. J Hum Nutr Diet 2011; 24: 487-495 [PMID: 21615553 DOI: 10.1111/j.1365-277X.2011.01162.x]
37. Menees SB, Maneerattannaporn M, Kim HM, Chey WD. The efficacy and safety of rifaximin for the irritable bowel syndrome: a systematic review and meta-analysis. Am J Gastroenterol 2012; 107: 28-35; quiz 36 [PMID: 22045120 DOI: 10.1038/ajg.2011.355]
38. Choi YK, Kraft N, Zimmerman B, Jackson M, Rao SS. Fructose intolerance in IBS and utility of fructose-restricted diet. J Clin Gastroenterol 2008; 42: 233-238 [PMID: 18223504 DOI: 10.1097/MCG.0b013e31802cbc2f]
39. Kripke SA, Fox AD, Berman JM, Settle RG, Rombeau JL. Stimulation of intestinal mucosal growth with intracolonic infusion of short-chain fatty acids. JPEN J Parenter Enteral Nutr 1989; 13: 109-116 [PMID: 2496241 DOI: 10.1177/0148607 189013002109]
40. Ruppin H, Bar-Meir S, Soergel KH, Wood CM, Schmitt MG. Absorption of short-chain fatty acids by the colon. Gastroenterology 1980; 78: 1500-1507 [PMID: 6768637]
41. Boutron-Ruault MC, Marteau P, Lavergne-Slove A, Myara A, Gerhardt MF, Franchisseur C, Bornet F, Eripolyp Study Group. Effects of a 3-mo consumption of short-chain fructooligosaccharides on parameters of colorectal carcinogenesis in patients with or without small or large colorectal adenomas. Nutr Cancer 2005; 53: 160-168 [PMID: 16573377 DOI: 10.1207/s15327914nc5302_5]
42. Tedelind S, Westberg F, Kjerrulf M, Vidal A. Anti-inflammatory properties of the short-chain fatty acids acetate and propionate: a study with relevance to inflammatory bowel disease. World J Gastroenterol 2007; 13: 2826-2832 [PMID: 17569118]
43. Dass NB, John AK, Bassil AK, Crumbley CW, Shehee WR, Maurio FP, Moore GB, Taylor CM, Sanger GJ. The relationship between the effects of short-chain fatty acids on intestinal motility in vitro and GPR43 receptor activation. Neurogastroenterol Motil 2007; 19: 66-74 [PMID: 17187590 DOI: 10.1111/j.1365-2982.2006.00853.x]
44. Kamath PS, Phillips SF, O'Connor MK, Brown ML, Zinsmeister AR. Colonic capacitance and transit in man: modulation by luminal contents and drugs. Gut 1990; 31: 443-449 [PMID: 2338271 DOI: 10.1136/gut.31.4.443]
45. Swarbrick ET, Hegarty JE, Bat L, Williams CB, Dawson AM. Site of pain from the irritable bowel. Lancet 1980; 2: 443-446 [PMID: 6106097 DOI: 10.1016/S0140-6736(80)91885-1]
46. Bourdu S, Dapoigny M, Chapuy E, Artigue F, Vasson MP, Dechelotte P, Bommelaer G, Eschalier A, Ardid D. Rectal instillation of butyrate provides a novel clinically relevant model of noninflammatory colonic hypersensitivity in rats. Gastroenterology 2005; 128: 1996-2008 [PMID: 15940632 DOI: 10.1053/j.gastro.2005.03.082]
47. Vanhoutvin SA, Troost FJ, Kilkens TO, Lindsey PJ, Hamer HM, Jonkers DM, Venema K, Brummer RJ. The effects of butyrate enemas on visceral perception in healthy volunteers. Neurogastroenterol Motil 2009; 21: 952-e76 [PMID: 19460106 DOI: 10.1111/j.1365-2982.2009.01324.x]
48. Otten MH, De Haas G, Van den Ende R. Colonic spread of 5-ASA enemas in healthy individuals, with a comparison of their physical and chemical characteristics. Aliment Pharmacol Ther 1997; 11: 693-697 [PMID: 9305477 DOI: 10.1046/ j.1365-2036.1997.00199.x]
49. Shen J, Obin MS, Zhao L. The gut microbiota, obesity and insulin resistance. Mol Aspects Med 2013; 34: 39-58 [PMID: 23159341 DOI: 10.1016/j.mam.2012.11.001]